EVX-01, a personalized cancer vaccine, induces potent T cell responses and durable disease control in advanced melanoma – 2-year follow-up
Dr. Muhammad Adnan Khattak (MBBS, FRACP, PhD), Director, Oncology, One Clinical Research, Hollywood Private Hospital & Edith Cowan University, Perth, WA, Australia
Muhammad A. Khattak (Perth, Australia), Paolo A. Ascierto (Naples, Italy) ,Carolina Cimminiello (Milano, Italy), Michael J. Chisamore (Whitehouse Station, United States of America), Rasmus Andersen (Copenhagen, Denmark), Thomas Strandet Jepsen (Hoersholm, Denmark), Daniela Kleine-Kohlbrecher (Hoersholm, Denmark), Mads Lausen (Horsholm, Denmark), Michail A. Pavlidis (Copenhagen, Denmark), Birgitte Rønø (Copenhagen, Denmark), Stine F. Thorsen (Hoersholm, Denmark), Thomas Trolle (Copenhagen, Denmark), Nadia Viborg (Hoersholm, Denmark), Benjamin Wolthers (Hoersholm, Denmark), Georgina V. Long (Sydney, Australia, NSW)
